June 26, 2026 | San Jose, California, USA
Anixa Biosciences, Inc. announced encouraging clinical updates from its two leading immunotherapy programs during the New York Academy of Sciences’ Frontiers in Cancer Immunotherapy Symposium, highlighting positive Phase 1 breast cancer vaccine results and promising survival observations from its ongoing lira-cel CAR-T therapy trial for recurrent ovarian cancer. The presentations reinforce the company’s strategy of developing innovative cancer immunotherapies through collaborations with Cleveland Clinic and Moffitt Cancer Center, marking another important milestone in its oncology pipeline.
Breast Cancer Vaccine Meets Key Phase 1 Endpoints
The company’s investigational breast cancer vaccine, developed in partnership with Cleveland Clinic, successfully achieved all major primary Phase 1 study endpoints, demonstrating a favorable safety profile and strong immune activation. According to the final clinical data, the vaccine generated protocol-defined immune responses in 74% of participants, while remaining safe and well tolerated at the maximum tolerated dose. The vaccine targets alpha-lactalbumin (α-lactalbumin), a protein normally expressed during lactation but found in several forms of breast cancer. By training the immune system to recognize this “retired” protein, the therapy aims to prevent tumor formation without damaging healthy tissue. Researchers believe this novel preventive immunotherapy could eventually provide a new strategy for women at high risk of developing breast cancer as well as patients requiring additional protection against disease recurrence.
CAR-T Therapy Shows Encouraging Survival Observations
Anixa also presented new findings from its ongoing Phase 1 clinical trial evaluating liraltagene autoleucel (lira-cel), an investigational CAR-T cell therapy designed for patients with recurrent platinum-resistant ovarian cancer. Developed in collaboration with Moffitt Cancer Center, lira-cel uses a unique Chimeric Endocrine Receptor T-cell (CER-T) approach that targets the follicle-stimulating hormone receptor (FSHR), which is highly expressed in ovarian cancer cells while remaining largely absent from healthy tissues. Early observations from the study revealed that multiple patients remain alive more than one year after treatment, providing encouraging evidence supporting continued clinical development. Although the Phase 1 trial primarily evaluates safety and dosing, these survival findings suggest the therapy may offer meaningful clinical benefit in a patient population with limited treatment options after multiple prior therapies.
Advertisement
Strategic Collaborations Strengthen Oncology Pipeline
The symposium presentations underscore Anixa Biosciences’ commitment to advancing next-generation cancer immunotherapies through collaborations with internationally recognized research institutions. Company Chairman and CEO Dr. Amit Kumar emphasized that both clinical programs continue to make significant progress while demonstrating the value of combining innovative science with leading academic expertise. The breast cancer vaccine and lira-cel program address two major unmet medical needs using distinct but complementary immunotherapy approaches, positioning the company with multiple opportunities in cancer treatment and prevention. As both programs continue advancing through clinical development, investors and oncology researchers will closely monitor future efficacy updates, expanded patient enrollment, and potential progression into later-stage clinical trials. The encouraging Phase 1 vaccine data together with positive survival observations from the ongoing CAR-T study reinforce Anixa’s growing presence in the evolving field of cancer immunotherapy, where innovative immune-based treatments continue to reshape the future of oncology care.
Source: Anixa Biosciences press release
